Suboxone (Buprenorphine HCl/Naloxone HCl) Patent Expiration, LOE Window & CMS Spending

Suboxone (Buprenorphine HCl/Naloxone HCl) by Indivior: FDA Orange Book LOE 2030-03-26, 7 AB generics, $959.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIndivior
FDA Application & PathwayN022410 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-03-26
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$959.8M
2024 Medicare Part D Spend$70.7M
2024 Medicaid Spend$889.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel